Celldex Therapeutics, Inc. (CLDX) — 10-Q Filings

10-Q Filings (6)

• Celldex Losses Widen on Soaring R&D for Barzolvolimab — Nov 10, 2025 Risk: high
  Celldex Therapeutics, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $177.4 million, up from $110.8 mil
• Celldex Cuts R&D Spend Amidst Continued Net Losses — Aug 7, 2025 Risk: high
  Celldex Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net loss
• Celldex Therapeutics Files Q1 2025 10-Q — May 8, 2025 Risk: low
  Celldex Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial position, including common stock, ret
• Celldex Therapeutics Q3 2024 Financial Update — Nov 6, 2024 Risk: medium
  Celldex Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $55.9 million and total liabilities of
• Celldex Therapeutics Q2 2024 Update: Cash Dips, Operations Continue — Aug 8, 2024 Risk: medium
  Celldex Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported cash and cash equivalents of $55.9 million as of June 30, 20
• Celldex Therapeutics Files 10-Q for Period Ending March 31, 2024 — May 6, 2024 Risk: low
  Celldex Therapeutics, Inc. (CLDX) filed a Quarterly Report (10-Q) with the SEC on May 6, 2024. Celldex Therapeutics, Inc. filed a 10-Q report for the quarterly

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX